IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Easy Mark who wrote (342)	4/3/1998 12:40:00 PM
From: Easy Mark	Read Replies (1) of 1510

This is my best comparison of T-cell technologies of Cell Genesys (CEGE) and IRC. Both companies offer therapies targeting the t-cells that harbor HIV and which cannot be killed by current drug therapies. IRC uses a vaccine derived from killed HIV from which the outer protein envelope (gp120) has been destroyed. The vaccine stimulates the immune system to attack the t-cells by recognizing the proteins (e.g. gp6, etc.) from the interior of HIV. CEGE takes blood from a patient and genetically engineers billions of normal t-cells to recognize the gp120 protein. These re-engineered t-cells are then injected into the patient and attack both the HIV and the t-cells that harbor HIV. This effect can boost the immune response when HIV has depleted the existing resevoir of t-cells. obervation: Vaccines targeting gp120 have proven ineffective for two reasons. 1) HIV mutates so recognition of gp120 does not occur properly. 2) Once HIV has infected a t-cell, the gp120 protein has been shed and only the internal proteins are presented. questions: Why should CEGE's technology be useful? IS my comparison faulty?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next